At this time, there are no generic Kapidex (dexlansoprazole) products available in the United States. This is because the medication is currently under the protection of a patent that prevents any companies from producing a generic version of the drug. The earliest predictable date that a generic version could become available is December 2020, when the patent expires.
Kapidex is made by Takeda Pharmaceuticals America, Inc. Currently, the drug is protected by patents that prevent any generic versions from being sold in the United States.
Starting April 2010, the name for Kapidex was officially changed to Dexilant™. The name was changed because it was too similar to the names of a few other drugs, leading to a few "mix-ups." Please see our Dexilant articles within eMedTV.com for current information about this medication.
When Will Generic Kapidex Be Available?
The first patent for Kapidex currently expires in December 2020. This is the earliest predictable date that a generic version of the drug could become available. However, there are other circumstances that could come up to extend or shorten the exclusivity period of Kapidex. This could include such things as lawsuits or other patents for specific Kapidex uses. Once Kapidex goes off patent, there may be several companies that will manufacture a generic Kapidex drug.
Is Dexlansoprazole a Generic Form of Kapidex?
The answer is no. Dexlansoprazole is the active ingredient in Kapidex but is not a generic version of the medication. What can be confusing is that, oftentimes, the active ingredient of any drug is referred to as the "generic name." The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off patent, and another company besides the original manufacturer must make the product.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed March 12, 2009.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click